ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) Director Lawrence Guiheen sold 10,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $13.92, for a total transaction of $139,200.00. Following the completion of the sale, the director directly owned 63,599 shares in the company, valued at $885,298.08. This trade represents a 13.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
ADMA Biologics Trading Up 1.2%
Shares of ADMA stock opened at $13.63 on Wednesday. The firm has a fifty day moving average of $10.73 and a 200-day moving average of $10.76. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of 17.70 and a beta of 0.65. ADMA Biologics Inc has a 52-week low of $7.21 and a 52-week high of $20.46. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.25 and a current ratio of 6.04.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.03. The business had revenue of $141.10 million for the quarter, compared to analyst estimates of $138.11 million. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.56%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.15 EPS. On average, equities research analysts forecast that ADMA Biologics Inc will post 0.82 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on ADMA shares. Cantor Fitzgerald lifted their price objective on ADMA Biologics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. Mizuho set a $18.00 price objective on ADMA Biologics in a research note on Thursday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Finally, Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.50.
View Our Latest Report on ADMA
Institutional Investors Weigh In On ADMA Biologics
Several institutional investors and hedge funds have recently made changes to their positions in ADMA. Allworth Financial LP increased its holdings in ADMA Biologics by 43.9% during the 3rd quarter. Allworth Financial LP now owns 11,735 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 3,582 shares in the last quarter. Entropy Technologies LP raised its position in ADMA Biologics by 234.4% in the 3rd quarter. Entropy Technologies LP now owns 75,592 shares of the biotechnology company’s stock valued at $758,000 after purchasing an additional 52,990 shares during the last quarter. Jump Financial LLC raised its position in ADMA Biologics by 156.1% in the 3rd quarter. Jump Financial LLC now owns 460,907 shares of the biotechnology company’s stock valued at $4,623,000 after purchasing an additional 280,907 shares during the last quarter. Caxton Associates LLP boosted its stake in ADMA Biologics by 5.8% in the third quarter. Caxton Associates LLP now owns 42,256 shares of the biotechnology company’s stock worth $424,000 after purchasing an additional 2,328 shares in the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in ADMA Biologics by 9.8% in the third quarter. Nantahala Capital Management LLC now owns 2,590,475 shares of the biotechnology company’s stock worth $25,982,000 after purchasing an additional 230,482 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.
About ADMA Biologics
ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.
Recommended Stories
- Five stocks we like better than ADMA Biologics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
